| An SI Board Since June 1998 |
| Posts |
SubjectMarks |
Bans |
| 14 |
0 |
0
|
|
Current Techology Corp. is a small Canadian Company that holds an exclusive worldwide license to ETG (Electrotrichnogenesis), a patented device that provides a clinically proven treatment for hair loss.
Controlled (double-blinded) clinical studies conducted at the Univ. of British Columbia demonstrated that Current Technologies ETG device generated regrowth or stopped hair loss in 96% of the study participants. Thes was subsequently confirmed by a multi-center study in the U.S. and Canada. The results have been published in prestigious peer-reviewed medical journals. The treatments are comfortable, safe and not associated with any adverse effects.
The company is now emerging from an R&D concern to an operating company. It has just received the CE Mark, the European equivalent to FDA approval in the U.S., to market their ETG Devices in Europe. FDA approval is expected sometime this fall. The Co. has signed distribution agreements in Britian, Ireland, Portugal, Spain, Germany and Switzerland with ongoing negotiations ocurring in Beligum, the Netherlands, Luxemberg, Italy and Turkey. In addition there 32 ETG treatment centers operating in 9 additional countries.
The stock is selling for approximately US$0.25/share and appears undervalued given its immense potential. The Co. is expected to turn profitable this year. Call Investor Relations (1-800-661-4247) to get their investor packet and research reports or visit their web site at www.currentech.com
VSE ONE Contacts: Sean Meegan or Don Gulliman
OTC:BB CRTCF
|
|
|
